

Press information 31 January 2007

New Oasmia-product ready for clinical trials

Oasmia Pharmaceutical's third patented product, Doxophos[®], is now ready to enter clinical trials. The trials are planned to commence during the fourth quarter of 2007.

Doxophos[®] contains the well-known active substance doxorubicin which is used for treatment worldwide of e.g. breast cancer and ovarian cancer. Doxorubicin is the most used cytostatic agent for the last 20 years. New treatment methods are continuously developed and the market grows steadily. The product has thereby a very large market potential. The entrance into clinical trials is another step in Oasmia's strategy for establishment on the world wide market for oncology products.

Oasmia is looking forward to the results of the trials. The company expects that the results will show medical advantages of Doxophos[®] compared to preparations used today. The product will strengthen Oasmia's already very solid product portfolio considerably. The world wide market for cytostatics is valued at 20 billion USD annually.

Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts in bio-organic chemistry. The company idea is to improve treatment of serious conditions, with a focus on oncology. This is done through development of semi-synthesised substances to a new generation of effective pharmaceuticals for various areas of therapy. Oasmia is noted on the NGM Nordic MTF. More information is available at www.ngm.se or at www.oasmia.com.

For more information, please contact Johan Edin, tel: +46 18 50 54 40, e-mail: johan@oasmia.com